CG Oncology Faces Growing Losses Despite Promising Drug Trials and Strong Cash Reserves

Company Overview:
CG Oncology, Inc. (NASDAQ: CGON) is a late-stage clinical biopharmaceutical company focused on developing its product candidate, cretostimogene grenadenorepvec, for bladder cancer treatment. The company is at a clinical stage and has not yet projected significant revenues without FDA approval.

Recent Developments:
- Initiated several clinical trials focused on high-risk bladder cancer, including the BOND-003 study.
- Entered partnerships with Lepu Biotech and Kissei Pharmaceutical, with commitments for future milestone payments and royalties.
- Established a note receivable of $25 million as part of a collaboration with SP Healthcare, indicating ongoing investment in development efforts.

Income Statement Highlights (three months ended March 31, 2025):

• Revenues: License and collaboration revenue decreased to $52,000 from $529,000 YoY.
• Total Operating Expenses: Increased to $42.3 million from $23 million, mainly due to R&D and administrative costs.
• Net Loss: Rose to $34.5 million compared to $16.9 million last year.
• Net Loss per Share: Increased to $0.45 from $0.36 YoY.

Positive Aspects:
- The company has substantial cash reserves, with cash, cash equivalents, and marketable securities totaling approximately $688.4 million.
- Interest income increased to $7.7 million, providing some financial cushioning against operating losses.

Negative Aspects:
- Significant operating losses continuing to grow, indicative of high operational expenses versus insufficient revenue generation.
- Accumulated deficit climbed to $252.4 million, raising concerns about the sustainability of operations without future revenue streams.

Cash Flow Overview:
- Cash used in operating activities totaled $29.3 million, with significant operational investments not yet leading to revenue.
- Investing activities resulted in a cash outflow of $186.8 million, primarily driven by marketable securities purchases.
- Financing activities contributed a minor cash inflow of $450, reflecting limited capital generation in recent periods.

Outlook and Future Considerations:
- The company aims to strengthen its commercial operations in anticipation of FDA approval for cretostimogene.
- Ongoing clinical trials and collaborations suggest a focus on expanding its market presence, though substantial additional funding may be required for future operations and development projects.